Search results
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
Zacks via Yahoo Finance· 1 year agoThe FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for...
Johnson & Johnson (JNJ) Down 6.9% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 year agoA month has gone by since the last earnings report for Johnson & Johnson (JNJ). Shares have lost...
AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan
Zacks via Yahoo Finance· 8 months agoAstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to...
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
Zacks via Yahoo Finance· 1 year agoIn J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara...
J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance
Zacks via Yahoo Finance· 2 years agoJohnson & Johnson’s JNJ second-quarter 2022 earnings came in at $2.59 per share, which beat the...
J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
Zacks via Yahoo Finance· 2 weeks agoJohnson & Johnson’s JNJ first-quarter 2024 earnings came in at $2.71 per share, which beat the Zacks...
Point radiopharma drug results disappoint in prostate cancer study
BioPharma Dive via Yahoo Finance· 4 months agoDive Brief: A targeted radiation drug being developed by Indianapolis-based Point BioPharma met its...
Johnson & Johnson Reports Mixed Q4 Earnings, Issues FY23 Guidance Edging Higher Than Street...
Benzinga via Yahoo Finance· 1 year agoJohnson & Johnson (NYSE: JNJ) has reported Q4 FY22 adjusted earnings of $2.35 per share, up 10% Y/Y...
Why Is Johnson & Johnson (JNJ) Down 0.2% Since Last Earnings Report?
Zacks via Yahoo Finance· 2 months agoIt has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have...
J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off
Zacks via Yahoo Finance· 6 months agoJohnson & Johnson’s JNJ third-quarter 2023 earnings came in at $2.66 per share, which beat the Zacks...